文献速递产科母胎医学

母胎医学会咨询系列#66:实体器官移植患者的孕前评估与妊娠管理

Society for Maternal-Fetal Medicine Consult Series #66: Prepregnancy evaluation and pregnancy management of patients with solid organ transplants.
PubMed 文献 · Am J Obstet Gynecol · 2023-04-22

过去30年育龄人群实体器官移植率上升,免疫抑制剂种类增多使妊娠更安全。本文回顾了妊娠实体器官移植受者的医学与产科管理,讨论了常见移植类型的围产结局和移植物排斥发生率,并基于现有证据给出21条管理推荐。

要点

  • 所有有妊娠可能的实体器官移植受者应在移植前评估及移植后妊娠前接受孕前咨询(最佳实践)。
  • 移植后或急性细胞性排斥发作后至少推迟妊娠1年,肺移植受者推迟2年(GRADE 1B)。
  • 妊娠前需移植物功能稳定且慢性合并症控制良好(GRADE 1B);使用霉酚酸或其他致畸免疫抑制剂时采用高效避孕(GRADE 1A)。

核心结论

  • 实体器官移植受者妊娠需多学科管理,孕前咨询、稳定移植物功能、调整免疫抑制剂及密切监测是改善母胎结局的关键。

研究设计与样本

  • 母胎医学会(Society for Maternal-Fetal Medicine)咨询系列,基于现有证据综述妊娠实体器官移植受者的医学与产科管理并给出推荐。

主要发现

  • 过去30年育龄人群实体器官移植率上升,免疫抑制剂种类增多使移植受者尝试和继续妊娠更安全。
  • 综述了最常见移植类型的围产结局和移植物排斥发生率。

关键数值与推荐

  • 推荐所有有妊娠可能的实体器官移植受者在移植前评估及移植后妊娠前接受孕前咨询(最佳实践)。
  • 推荐移植后或急性细胞性排斥发作后至少推迟妊娠1年,肺移植受者推迟2年(GRADE 1B)。
  • 推荐妊娠前移植物功能稳定且慢性合并症控制良好(GRADE 1B)。
  • 推荐使用霉酚酸或其他已知致畸免疫抑制剂的育龄移植受者采用高效避孕(GRADE 1A)。
  • 推荐计划妊娠的移植受者孕前转换为合适免疫抑制方案以建立稳定药物剂量和移植物功能(GRADE 1C)。

临床怎么用

  • 妊娠期和产褥期密切监测血清药物水平以指导免疫抑制治疗剂量(GRADE 1C)。
  • 推荐妊娠或计划妊娠的移植受者孕前和孕期接种所有指征疫苗(GRADE 1C)。
  • 鉴于巨细胞病毒感染对胎儿和新生儿的后遗症风险,建议移植受者理想情况下在尝试妊娠前完成指征抗病毒预防或治疗(GRADE 2B)。
  • 推荐每日低剂量阿司匹林预防子痫前期,并降低肾移植受者肾移植物衰竭风险(GRADE 1C)。
  • 推荐妊娠移植受者获得心理健康专家服务并在孕期和产褥期接受抑郁筛查(最佳实践)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The rate of solid organ transplant in reproductive-aged patients has increased in the past 3 decades. Concurrently, the range of medical immunosuppressive agents has increased, making it safer for reproductive-aged individuals who have received transplants to attempt and continue a pregnancy. In this Consult, we review the general considerations and contemporary approach to medical and obstetrical management of pregnant solid organ transplant recipients, discuss the perinatal outcomes and incidence of graft rejection specific to the most common types of organ transplants, and provide management recommendations based on the available evidence. The following are Society for Maternal-Fetal Medicine recommendations: (1) we recommend that all solid organ transplant recipients capable of pregnancy be offered prepregnancy counseling as part of the pretransplant evaluation and before any posttransplant pregnancy (Best Practice); (2) we recommend deferring pregnancy for at least 1 year (except for lung transplant recipients in which case a 2-year deferral is recommended) following solid organ transplant or any episode of acute cellular rejection (GRADE 1B); (3) we recommend that solid organ transplant recipients have stable allograft function and optimal control of chronic medical comorbidities before attempting pregnancy (GRADE 1B); (4) we recommend that solid organ transplant recipients of reproductive age use highly effective contraception when on mycophenolate or other immunosuppressive agents with known teratogenic risk (GRADE 1A); (5) we recommend that solid organ transplant recipients contemplating pregnancy transition to an appropriate immunosuppressive regimen before attempting pregnancy to establish stable medication dosing and allograft function (GRADE 1C); (6) we recommend close monitoring of serum drug levels during pregnancy and the postpartum period to guide immunosuppressive therapy dosing (GRADE 1C); (7) we recommend that solid organ transplant recipients who are pregnant or contemplating pregnancy receive all indicated vaccinations before and during pregnancy (GRADE 1C); (8) given the risk of fetal and neonatal sequelae secondary to cytomegalovirus infection in pregnancy, we suggest that solid organ transplant recipients ideally complete any indicated antiviral prophylaxis or treatment before pursuing pregnancy (GRADE 2B); (9) we recommend daily low-dose aspirin prophylaxis to reduce the risk for preeclampsia in pregnant solid organ transplant recipients and to reduce the risk for renal allograft failure in renal transplant recipients (GRADE 1C); (10) as for all pregnant people, we recommend that pregnant solid organ transplant recipients have access to mental health specialists and receive screening for depression during pregnancy and the postpartum period (Best Practice); (11) because of the increased incidence of fetal growth restriction and common coexisting medical morbidities, we recommend serial assessment of fetal growth every 4 to 6 weeks throughout gestation after the anatomic survey (GRADE 1C); (12) we suggest antenatal surveillance from 32 weeks of gestation unless other fetal or maternal factors are identified in which case initiation of surveillance at an earlier gestational age is indicated (GRADE 2C); (13) we recommend that renal function be assessed before pregnancy or in early pregnancy in all solid organ transplant recipients (kidney and non-kidney) (GRADE 1C); (14) we suggest individualized delivery timing for pregnant solid organ transplant recipients and to consider delivery at between 37+0/7 and 39+6/7 weeks of gestation; in the absence of other indications, we suggest delivery by 39+6/7 weeks gestation for pregnant solid organ transplant recipients (GRADE 2B); (15) given that a trial of labor is associated with a high success rate and lower neonatal morbidity without increasing maternal morbidity or compromising graft survival, we recommend that cesarean delivery be reserved for medical obstetrical indications in solid organ transplant recipients (GRADE 1C); (16) we recommend that blood pressure targets in pregnant renal transplant recipients with chronic hypertension follow guidelines for nonpregnant recipients with a target blood pressure of ≤130/80 mm Hg (GRADE 1C); (17) we recommend monthly urine cultures to screen for asymptomatic bacteriuria with treatment if positive to protect the graft in pregnant renal transplant recipients (GRADE 1C); (18) we recommend that pregnancies in pancreas-kidney transplant recipients be managed in a similar way as those of renal transplant recipients alone (GRADE 1C); (19) we recommend characterizing the underlying condition that led to liver transplantation and assessing baseline renal function in pregnant liver transplant recipients. (GRADE 1C); (20) because of the cardiovascular demand of pregnancy and the unique physiological implications of cardiac transplantation, we recommend that pregnant heart transplant recipients receive multidisciplinary care with cardiology, cardiac and/or obstetrical anesthesiology, and maternal-fetal medicine specialists (Best Practice); and (21) we recommend careful delivery planning to minimize hemodynamic stress (including considering operative vaginal delivery to minimize Valsalva) and suggest continuous intrapartum or intraoperative electrocardiographic monitoring for heart transplant recipients (GRADE 1C).

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Irani RA, Coscia LA, Chang E, et al. Society for Maternal-Fetal Medicine Consult Series #66: Prepregnancy evaluation and pregnancy management of patients with solid organ transplants. Am J Obstet Gynecol. 2023. PMID: 37088276. doi:10.1016/j.ajog.2023.04.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。